Patrick R. Hagner, Ph.D.
Affiliations: | 2010 | Molecular Medicine | University of Maryland School of Medicine, Baltimore, MD, United States |
Area:
Molecular BiologyGoogle:
"Patrick Hagner"Parents
Sign in to add mentor| Tony Passaniti | grad student | 2010 | University of Maryland Medical School | |
| (Targeting the translational machinery as a novel treatment strategy for non -Hodgkin lymphoma.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Apollonio B, Spada F, Petrov N, et al. (2023) Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma. The Journal of Clinical Investigation |
| Ribrag V, Chavez JC, Boccomini C, et al. (2022) Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. Ejhaem. 3: 139-153 |
| Wu W, Nelson G, Koch R, et al. (2021) Overcoming IMiD Resistance in T-cell Lymphomas Through Potent Degradation of ZFP91 and IKZF1. Blood |
| Michot JM, Bouabdallah R, Vitolo U, et al. (2020) Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. The Lancet. Haematology |
| Risueno A, Hagner PR, Towfic F, et al. (2020) Leveraging Gene Expression Subgroups to Classify DLBCL Patients and Enrich for Clinical Benefit to a Novel Agent. Blood |
| Carpio C, Bouabdallah R, Ysebaert L, et al. (2020) Avadomide monotherapy in relapsed/refractory DLBCL: Safety, efficacy, and a predictive gene classifier. Blood |
| Mehta-Shah N, Chavez JC, Abrisqueta P, et al. (2020) Phase I/II study of avadomide (CC-122) in combination with R-CHOP for newly diagnosed DLBCL. Journal of Clinical Oncology. 38: 3501-3501 |
| Chiu H, Trisal P, Bjorklund C, et al. (2019) Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma. British Journal of Haematology |
| Hagner PR, Chiu H, Chopra VS, et al. (2019) Interactome of Aiolos/Ikaros in Diffuse Large B-Cell Lymphoma (DLBCL) Reveals Novel Combination of Cereblon Modulators (CELMoD) and Histone Deacetylase (HDAC) Inhibitors Blood. 134: 306-306 |
| Hagner PR, Waldman M, Gray FD, et al. (2019) Targeting B-Cell Maturation Antigen (BCMA) with CC-93269, a 2+1 T Cell Engager, Elicits Significant Apoptosis in Diffuse Large B-Cell Lymphoma Preclinical Models Blood. 134: 1580-1580 |